Experienced Australian CRO attains Medidata accreditation to offer enhanced clinical trial services

You are here

Media contact:
Susan Fitzpatrick-Napier
DMG
Australia: +61 2 8006 0424
USA: +1650 7985238
EMAIL: susan@dmgpr.com

NOVOTECH EXPANDS PARTNERSHIP WITH MEDIDATA SOLUTIONS
Experienced Australian CRO attains Medidata accreditation to offer enhanced clinical trial services

Sydney, Australia, 31 May, 2013 – Novotech, the largest Australia based CRO and fast growing in Asia, has expanded its relationship with Medidata Solutions (NASDAQ:MDSO) by achieving accreditation for Medidata Rave®, an industry leading system for electronic data capture (EDC) and clinical data management (CDM).

Novotech joined the Medidata Partner Program in 2010 to support its offering of data management solutions for biotechnology and pharmaceutical clients conducting Phase I-III trials, and has since expanded its use of Medidata technology in its clinical trials, including Rave for data management and Medidata Balance® for randomisation services. Novotech takes advantage of Medidata’s cloud-based technology to streamline and enhance clinical processes for their clients.

Novotech CEO Alek Safarian said their Rave accreditation means Novotech clients can expect further streamlining of EDC delivery from the CRO, using a single data platform across complex regional studies.

“This is an important milestone for us. Being a regionally focused CRO, it is critical for us to offer high-end solutions to smaller biotechnology and pharmaceutical clients with whom we work. We are proud to be among the leading service providers accredited in Medidata Rave, offering a full array of eClinical solutions catering to this sector of the market,” said Safarian.

“We congratulate Novotech for being the first Australian based CRO accredited in Medidata’s leading EDC/CDM system,” said Steve Heath, vice president of channel sales at Medidata Solutions, “With our partnership expansion, Novotech now combines their deep expertise and best practices for leveraging Medidata’s cloud-based technology to further benefit sponsors’ clinical trials.”

About Novotech

Established in 1996 and headquartered in Sydney, Novotech is focused on the Asia Pacific region, running clinical trials in all key regional markets including China, India, Australia, Taiwan and South Korea. Novotech also has worldwide reach through the company's network of strategic partners. Novotech, described by Frost & Sullivan as the best in its industry class for Australia-based CROs, brings its global reputation for high quality service and regional expertise to the high-growth Asia Pacific area. For more information, please visit www.novotech-cro.com.

About Medidata Solutions

Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials.

Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.